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and elevated pretransplant serum ferritin seems to adversely affect prognosis with myeloablative transplantation 2, 3 for other diseases as well, primarily because of increased non-relapse mortality. We analyzed patients who underwent nonmyeloablative preparation for allogeneic transplantation to determine whether the presence of iron overload was also an adverse prognostic factor for patients undergoing nonmyeloablative transplants.
A total of 64 patients undergoing nonmyeloablative allogeneic transplantation for various disorders between 12/00 and 12/06 had pretransplant ferritin levels measured within 100 days preceding transplantation. Patient and transplant characteristics are summarized in Table 1 . Median ferritin was 961 ng/ml (range, 30-6251 ng/ml).
On the basis of earlier publications, 2, 3 we analyzed the data using 1000 ng/ml as a cutoff for pretransplantation serum ferritin. A total of 32 patients with ferritin o1000 ng/ml had better overall survival than those with ferritin 41000 ng/ml (P ¼ 0.047). Further analysis by recursive partitioning identified significantly better survival for patients with ferritin p1615 ng/ml (n ¼ 45) compared with those with ferritin 41615 ng/ml (n ¼ 19; P ¼ 0.012), as shown in Figure 1 . Median follow-up for surviving patients was 19.2 months (range, 2.0-59.5 months).
Multivariate analysis for overall survival included the following variables: age, gender, diagnosis, interval from diagnosis to transplant, extent of prior therapy before transplant, ferritin level, albumin, aspartate transaminase, alkaline phosphatase, bilirubin, lactate dehydrogenase, donor source, degree of HLA match, donor to recipient gender and CD34 þ dose. Of these, only ferritin 41615 ng/ml (P ¼ 0.010, HR ¼ 2.74), older age (P ¼ 0.049, HR ¼ 1.63) and prior transplantation (P ¼ 0.002, HR ¼ 5.78) were adverse prognostic factors. The addition of albumin, a negative acute phase reactant, did not change the prognostic impact of 
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2 Causes of death in the low and high ferritin groups are given in Table 2 .
Inferior survival in patients with elevated ferritin was related to both higher rates of treatment-related mortality (P ¼ 0.51) and relapse mortality (P ¼ 0.23), neither of which reached statistical significance. Incidence of acute GVHD (P ¼ 0.54) and chronic GVHD (P ¼ 0.82) were not significantly different between the groups. Cumulative incidence of relapse was 21.3% in the low ferritin group and 36.2% in the high ferritin group (P ¼ 0.24) and of treatment-related mortality was 27.9% in the low ferritin group and 36.7% in the high ferritin group (P ¼ 0.51).
To our knowledge, this is the first report that elevated pretransplant serum ferritin is an independent adverse risk factor in patients undergoing nonmyeloablative transplantation. The association of ferritin with iron overload and its influence on hematopoietic SCT outcomes requires further prospective validation.
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